Skip to main content

Multimedia

NEUROPSYCHIATRY TRACK
In this video, Joohi Jimenez‑Shahed, MD, explains a 3-year, open-label study which evaluated the long-term efficacy and safety of deutetrabenazine, a treatment for the movement disorder tardive…
In this video, Psych Congress 2020 presenter Timothy Wilens, MD, provides strategies clinicians can use when treating a patient with both attention-deficit/hyperactivity disorder (ADHD) and substance…
NEUROPSYCHIATRY TRACK
Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged…
Psych Congress 2020 speaker Joseph F. Goldberg, MD, details factors that could influence a patient's response to a treatment for bipolar disorder, and how clinicians can address them.
Psych Congress 2020 presenter Timothy Wilens, MD, discusses the ways in which early treatment can improve outcomes in patients with attention-deficit/hyperactivity disorder (ADHD). 
Psych Congress 2020 speaker Marc E. Agronin, MD, shares strategies that mental health clinicians can use to adjust psychopharmacologic treatment and dosages for geriatric patients.
Bernhard T. Baune, PhD, MD, head of the Department of Mental Health at the University of Münster, Germany, discusses the occurrence of cognitive deficits in patients with various psychiatric…
Psych Congress 2020 cochair Vladimir Maletic, MD, MS, gives the latest updates on adult-onset attention deficit/hyperactivity disorder (ADHD).
Psych Congress 2020 presenter Timothy Wilens, MD, discusses the negative outcomes associated with attention-deficit/hyperactivity disorder (ADHD) that is left untreated.
Joseph F. Goldberg, MD, explains which clinical characteristics of a patient could affect their response to a treatment for bipolar disorder.
Back to Top